Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences

Annals of the Rheumatic Diseases

Volumn 75, Issue 5, 2016, Pages 942-943

  Gulácsi, László ^a   Rencz, Fanni ^a,b   Poór, Gyula ^c   Szekanecz, Zoltán ^d   Brodszky, Valentin ^a   Baji, Petra ^a   Péntek, Márta ^a,e  

^a Institute of Data Analytics and Information Systems   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e Pest Megyei Flor Ferenc Korhaz   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; BULGARIA; CHRONIC INFLAMMATION; CORRELATIONAL STUDY; CROHN DISEASE; CZECH REPUBLIC; ECONOMIC ASPECT; HEALTH CARE ACCESS; HUMAN; HUNGARY; LETTER; POLAND; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; ROMANIA; SLOVAKIA; ULCERATIVE COLITIS; ARTHRITIS; CHRONIC DISEASE; ECONOMICS; GROSS NATIONAL PRODUCT; HEALTH CARE DELIVERY; INFLAMMATION; STATISTICS AND NUMERICAL DATA;

ARTHRITIS; BIOLOGICAL THERAPY; CHRONIC DISEASE; GROSS DOMESTIC PRODUCT; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFLAMMATION;

EID: 84959432278     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208741     Document Type: Letter

References (9)

1. Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008;8(Suppl 2):S61-86.
2. Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, et al. Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy 2012;104:76-83.
3. Laires PA, Exposto F, Mesquita R, et al. Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur J Health Econ 2013;14:875-85.
4. Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Ann Rheum Dis 2014;73:2010-21.
5. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206.
6. Pentek M, Poor G, Wiland P, et al. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ 2014;15(Suppl 1):S35-43.
7. Rencz F, Pentek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol 2015;21:1728-37.
8. Rencz F, Kemeny L, Gajdacsi JZ, et al. Use of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol Venereol 2015;29:2222-30.
9. Gulacsi L, Rencz F, Pentek M, et al. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. Eur J Health Econ 2014;15(Suppl 1):S27-34.